LEAH Labs engineers CAR-T cells to treat B-cell lymphoma in dogs, providing a curative therapy that has successfully put dogs into remission. This approach not only addresses the significant cancer burden affecting six million dogs annually but also contributes to advancements in CAR-T cell therapies for human applications.
Funding
$475K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ASGCNSRMFounders
Product
Problem
Six million dogs are affected by cancer annually, with B-cell lymphoma being a common and aggressive form. Current treatment options for canine lymphoma often have limited efficacy and can be associated with significant side effects.
Solution
LEAH Labs engineers CAR-T cell therapies specifically for treating B-cell lymphoma in dogs. This approach involves modifying the dog's own immune cells to recognize and destroy cancerous B-cells. The CAR-T cell therapy offers the potential for a curative treatment, inducing remission in canine patients. Furthermore, advancements in canine CAR-T cell therapies can inform and accelerate the development of similar treatments for human cancers.
Target Audience
The primary target audience includes veterinary oncologists and pet owners seeking advanced treatment options for dogs diagnosed with B-cell lymphoma.
Features
- Autologous CAR-T cell therapy, utilizing the patient's own immune cells to minimize rejection risk.
- Engineered CAR-T cells designed to specifically target B-cell lymphoma cells in dogs.
- Clinical trials demonstrating successful remission in dogs with B-cell lymphoma.
- Development of novel CAR-T cell constructs with enhanced efficacy and safety profiles.